Design Therapeutics
Melanie Bell began their career as an Undergraduate Researcher at Kansas State University in 2007. Melanie then moved to Ionis Pharmaceuticals, Inc. in 2010, where they held the roles of Research Associate, Senior Research Associate, Assistant Director, and Scientist. In 2020, they joined Design Therapeutics as a Scientist.
Melanie Bell attended the University of Florida from 2005 to 2007, studying Chemistry. Melanie then transferred to Kansas State University and earned a Bachelor of Science degree in Biochemistry in 2010.
This person is not in the org chart
Design Therapeutics
1 followers
Design Therapeutics is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs™), designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.